An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy
in children and adolescents with Phelan-McDermid Syndrome.